Modified polynucleotides for the production of oncology-related proteins and peptides
AssigneeModernaTX, Inc.
InventorsAntonin De Fougerolles, Justin Guild
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
Claims12
A pharmaceutical composition comprising a plurality of lipid nanoparticles comprising a cationic lipid, a non-cationic lipid, cholesterol, and a PEG lipid, wherein the plurality of lipid nanoparticles has a mean particle size of between 80 nm and 150 nm and encapsulate an mRNA comprising:
- (a) an open reading frame encoding an oncology-related protein and consisting of nucleotides selected from N1-methyl-pseudouridine, cytidine, adenosine, and guanosine;
- (b) a 5′-untranslated region (UTR);
- (c) at least one 5′ cap structure;
- (d) a 3′-UTR;
- and
- (e) a 3′ tailing sequence of linked nucleosides.
Dependencies are inferred from the claim text.